Evidence Hub

Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?

Rawla P, Sunkara T, Ofosu A, Gaduputi V

World journal of gastrointestinal pharmacology and therapeutics, 2018

73 citations

Abstract

The modern lifestyle caters to an increase in the incidence of peptic ulcer disease, gastroesophageal reflux disease and several other acid-related conditions of the gut.The drugs to prevent these conditions work either through H2 receptor blockade or inhibition of the H + , K + ATPase enzyme.Although proton pump inhibitors have been proven to be efficacious, they have a slow onset of action with limited resolution of symptoms in most patients.Potassium-competitive acid blockers (P-CABs) are novel drugs that bind reversibly to K + ions and block the H + , K + ATPase enzyme, thus preventing acid production.P-CABs have a fast onset of action and have dose-dependent effects on acid production.Animal studies exist that differentiate the better results of P-CABs from proton pump inhibitors; further human trials will give a comprehensive picture of the results and will help to elucidate the therapeutic benefits of this new group of drugs.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free